Results 11 to 20 of about 349,757 (388)
Antibody drug conjugates [PDF]
Indian Journal of Medical and Paediatric Oncology, 2020 Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj +7 more sources
Antibody–drug conjugates [PDF]
Proceedings of the National Academy of Sciences, 2013 Ideally, targeted therapies attack diseased cells while leaving healthy ones alone. It’s a strategy that could result in more effective treatments for cancer (or other diseases) with fewer toxic side effects than traditional chemotherapies. A burgeoning class of targeted therapies, called antibody–drug conjugates (ADC), deliver dual therapies in a ...
Beck, Alain, Reichert, Janice M.
+8 more sources
Antibody-Drug Conjugates [PDF]
Pharmaceutical Research, 2015 Antibody-drug conjugates (ADCs) are an exciting and new class of therapeutic modalities that have gained significant traction over the past few years – specifically in the field of oncology. With the recent approvals of CD-30 directed Adcetris® (brentuximab vedotin) and the Her2 targeted Kadcyla® (ado-trastuzumab emtansine) and hundreds of other ADCs ...
Ashutosh A, Kulkarni +1 more
+7 more sources
Practical oncology, 2023 This article is a literature review of the available data on the history of origin, mechanism of action, and the main currently available conjugate-linked monoclonal antibodies. The use of conjugate-linked monoclonal antibodies in the therapy of both solid and hematological malignancies is a promising direction of anti-tumor therapy.
E.O. Stepanova +2 more
+5 more sources
Antibody-Drug Conjugates [PDF]
Journal of Nihon University Medical Association, 2017 Abstract Antibody–drug conjugates (ADCs) are designed with the purpose of delivering small-molecule cytotoxic drug to antigen-expressing tumor cells by harnessing the specificity, biodistribution, and pharmacokinetics of antibodies. ADCs are comprised of three components: the antibody, the linker, and the cytotoxic agent.
Amit Kumar +4 more
+5 more sources
Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
Pharmaceutics, 2022 As one of the major therapeutic options for cancer treatment, chemotherapy has limited selectivity against cancer cells. Consequently, this therapeutic strategy offers a small therapeutic window with potentially high toxicity and thus limited efficacy of
Rotimi Sheyi +2 more
semanticscholar +1 more source
Communications Medicine, 2021 Lee et al. use an antibody-drug conjugate to treat pathologic ocular neovascularization in mouse models. The antibody-drug conjugate targets PDGFRβ-expressing pericytes, with similar therapeutic effects to an anti-VEGF agent and with limited unwanted ...
Seok Jae Lee +10 more
doaj +1 more source
Molecular Cancer Therapeutics, 2021 Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody–drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a ...
D. Okajima +22 more
semanticscholar +1 more source
Blood, 2022 In this Blood Spotlight, Calabretta and colleagues describe the mechanism of action of loncastuximab tesirine, an anti-CD19 antibody-drug conjugate. They discuss data from the first phase 1 and 2 trials of the drug in patients with relapsed or refractory
Eleonora Calabretta +2 more
semanticscholar +1 more source
Nature Communications, 2023 Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab′)2 fragmented vascular endothelial growth factor receptor 2 antibody (anti-VEGFR2 (F(ab′)
Di Liu +12 more
doaj +1 more source